Clinical News-CliniExpert

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

Tuesday, March 17, 2020 - NEW YORK & MAINZ, Germany--(BUSINESS WIRE) -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed

Regeneron Announces Important Advances in Novel COVID-19 Antibody Program

TARRYTOWN, N.Y., March 17, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktai

NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins in Seattle

March 16, 2020 -- A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Resear

Sanofi and Regeneron Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in p

Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

NEW BRUNSWICK, N.J., March 13, 2020 -- Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC

Update on Phase III GY004 Trial for Cediranib Added to Lynparza in Platinum-Sensitive Relapsed Ovarian Cancer

12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by

New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020

BOSTON--(BUSINESS WIRE) March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first

Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study

BOSTON--(BUSINESS WIRE) March 10, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1b trial evaluating the company’s investigational toll-like receptor 7 (TLR7) agonis

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer

RARITAN, NJ, March 10, 2020 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designati

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

VANCOUVER, Washington, March 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ant

Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease

WATERTOWN, Mass.--(BUSINESS WIRE) -- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies fo

AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19

NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) today confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the e